A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia
- PMID: 17596915
- DOI: 10.1016/j.schres.2007.03.033
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia
Abstract
Dopamine D1 receptors play an important role in memory and cognition in non-human primates. Dopamine D1 agonists have been shown to reverse performance deficits in both aged non-human primates and in primates with lesions to dopamine systems. This study explored whether a single dose of the first full D1 agonist dihydrexidine (DAR-0100) would cause changes in brain activity (perfusion) in dopamine-rich brain regions. We used a new gadolinium-contrast magnetic resonance perfusion scanning technique to measure brain activity. A within-subject cross-over double-blind randomized design was used in 20 adults with SCID-diagnosed schizophrenia. Each morning at 0800 h, they were scanned on a 3.0 T MRI scanner for perfusion. They then received either 20 mg of dihydrexidine, or placebo, subcutaneously over 15 min. Over the next 45 min, they had intermittent MRI scans. Two days later, they had a repeat of the Day 1 schedule, but received the opposite treatment from that given on the first day. Within-day, as well as between-day, comparisons were made to test for perfusion effects of dihydrexidine. Analysis revealed that dihydrexidine induced a significant increase in both prefrontal and non-prefrontal perfusion compared to placebo. The greatest increases occurred approximately 20 min after dihydrexidine infusion, consistent with the short pharmacokinetic half-life of dihydrexidine. These data are consistent with the hypothesis formulated from studies of non-human primates that dihydrexidine and other D1 agonists may be able to modulate prefrontal dopaminergic function.
Similar articles
-
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.Schizophr Res. 2007 Jul;93(1-3):42-50. doi: 10.1016/j.schres.2007.03.011. Epub 2007 Apr 30. Schizophr Res. 2007. PMID: 17467956 Clinical Trial.
-
Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.Neuropsychopharmacology. 2015 Jan;40(2):446-53. doi: 10.1038/npp.2014.192. Epub 2014 Jul 30. Neuropsychopharmacology. 2015. PMID: 25074637 Free PMC article. Clinical Trial.
-
A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex?Neuroscience. 2004;124(1):33-42. doi: 10.1016/j.neuroscience.2003.11.016. Neuroscience. 2004. PMID: 14960337
-
Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.Biol Psychiatry. 2017 Jan 1;81(1):67-77. doi: 10.1016/j.biopsych.2015.12.028. Epub 2016 Jan 18. Biol Psychiatry. 2017. PMID: 26946382 Free PMC article. Review.
-
Dihydrexidine--the first full dopamine D1 receptor agonist.CNS Drug Rev. 2004 Fall;10(3):230-42. doi: 10.1111/j.1527-3458.2004.tb00024.x. CNS Drug Rev. 2004. PMID: 15492773 Free PMC article. Review.
Cited by
-
A Dopamine D1 Agonist Versus Methylphenidate in Modulating Prefrontal Cortical Working Memory.J Pharmacol Exp Ther. 2022 Aug;382(2):88-99. doi: 10.1124/jpet.122.001215. Epub 2022 Jun 5. J Pharmacol Exp Ther. 2022. PMID: 35661631 Free PMC article.
-
The treatment of cognitive impairment in schizophrenia.Pharmacol Biochem Behav. 2011 Aug;99(2):245-53. doi: 10.1016/j.pbb.2010.11.009. Epub 2010 Nov 27. Pharmacol Biochem Behav. 2011. PMID: 21115035 Free PMC article. Review.
-
Characterization of behavioral changes in T-maze alternation from dopamine D1 agonists with different receptor coupling mechanisms.Psychopharmacology (Berl). 2023 Oct;240(10):2187-2199. doi: 10.1007/s00213-023-06440-5. Epub 2023 Aug 14. Psychopharmacology (Berl). 2023. PMID: 37578525 Free PMC article.
-
Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.Clin Pharmacokinet. 2021 Jan;60(1):79-88. doi: 10.1007/s40262-020-00911-0. Clin Pharmacokinet. 2021. PMID: 32533536 Free PMC article.
-
Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.J Med Chem. 2011 Aug 11;54(15):5508-21. doi: 10.1021/jm200334c. Epub 2011 Jul 14. J Med Chem. 2011. PMID: 21714510 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical